Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

EDIT 10.18.2024

Full Press ReleaseSEC FilingsOur EDIT Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
  • 01.06.2025 - Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
PDF Version
Webinar to be held on Tuesday, October 22, at 8:00 a.m. ET

CAMBRIDGE, Mass.,Oct. 18, 2024(GLOBE NEWSWIRE) --Editas Medicine, Inc.(Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a Company-sponsored webinar on Tuesday, October 22, 2024, at 8:00 a.m. ET to share achievement ofin vivopreclinical proof of concept data and business development and financial updates.

Webinar Presentation Details:The live and archived webcast of the Company’s webinar presentation will be accessible through thiswebcast link, or through theEvents & Presentationspage of the “Investors” section of the Company’s website.

A replay of the webinar will be available upon conclusion of the webinar in the Investors section of theEditas Medicinewebsite athttps://www.editasmedicine.com/.

AboutEditas MedicineAs a clinical-stage gene editing company,Editas Medicineis focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world.Editas Medicineaims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.Editas Medicineis the exclusive licensee of Broad Institute’s Cas12a patent estate andBroad Instituteand Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visitwww.editasmedicine.com.

Media and Investor Contact:Cristi Barnett(617) 401-0113cristi.barnett@editasmed.com

Primary Logo

Source: Editas Medicine, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com